What does SH9 stand for?

In a phase I study that included 26 men with severe hemophilia A, a single infusion of a recombinant, pegylated liposome formulation of factor VIII resulted in a near doubling of the bleed-free interval compared with standard factor VIII, said Steven Pipe, MD, of the University of Michigan in Ann Arbor.

SWIFTLY-HA will include pediatric patients with hemophilia A, including previously treated patients with severe hemophilia A (FVIII: C activity less than 1 percent).

Open label study investigating the efficacy of prophylactic versus on-demand rFVIII-FS treatment In another presentation, (3) data from an open label clinical study that enrolled 20 adult men with severe hemophilia A (with and without target joints) demonstrated that patients who were changed from on-demand to prophylactic (preventive) infusions of rFVIII-FS had significantly reduced median joint bleeds per 6-month treatment period (zero events versus 15.

In the recent study, scientists removed a piece of skin from the arms of six people with severe hemophilia A.

started a Phase I study to evaluate the use of gene therapy for delivering Factor VIII (FVIII) to patients with severe hemophilia A.

If untreated, patients with severe hemophilia A have a greatly reduced life expectancy.

Food and Drug Administration (FDA) has approved routine prophylaxis with Kogenate(R) FS Antihemophilic Factor (Recombinant) to reduce the frequency of bleeding episodes and the risk of joint damage in patients aged 0-16 years with severe hemophilia A with no pre-existing joint damage.

He and his colleagues at Vanderbilt University in Nashville and The Orthopedic Hospital in Los Angeles analyzed mutations in the Factor VIII genes of 30 patients with severe hemophilia A and 17 patients with milder forms of the disorder.